Benign Prostatic Hyperplasia: A Brief Overview of Pathogenesis, Diagnosis, and Therapy

Techniques in Vascular and Interventional Radiology

Volumn 15, Issue 4, 2012, Pages 261-264

  Priest, Ryan ^a   Garzotto, Mark ^a   Kaufman, John ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; LUTS

Indexed keywords

ALFUZOSIN; CREATININE; DOXAZOSIN; NITRITE; PROSTATE SPECIFIC ANTIGEN; SILODOSIN; TAMSULOSIN; TERAZOSIN; TESTOSTERONE;

ANATOMY; ANUS SPHINCTER; APOPTOSIS; ARTICLE; BLADDER DYSFUNCTION; BLOOD CELL COUNT; CELL PROLIFERATION; DIGITAL RECTAL EXAMINATION; DISEASE COURSE; DISEASE SEVERITY; FLUID INTAKE; GLUCOSURIA; HEALTH STATUS; HEMATURIA; HOLMIUM LASER; HUMAN; KETONURIA; KIDNEY FAILURE; LOWER URINARY TRACT SYMPTOM; MONOTHERAPY; NOCTURIA; PATHOGENESIS; POLYURIA; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROTEINURIA; PYURIA; QUALITY OF LIFE; SEXUAL FUNCTION; SMOOTH MUSCLE TONE; URINALYSIS; VASCULARIZATION; WATCHFUL WAITING;

HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 84870873751     PISSN: 10892516     EISSN: 15579808     Source Type: Journal    
DOI: 10.1053/j.tvir.2012.10.001     Document Type: Article

References (10)

1. Lee C., Kozlowski J., Grayhack J. Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate 1997, 31:131.
2. Platz E.A., Smit E., Curhan G.C., et al. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology 2002, 59:877.
3. American Urological Association: Guideline on the Management of Benign Prostatic Hyperplasia (BPH). Revised 2010.
4. Kortt M.A., Bootman J.L. The economics of benign prostatic hyperplasia treatment: A literature review. Clin Ther 1996, 18:1227.
5. Saigal C.S., Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. Urology 2005, 173:1309-1313.
6. McNeal J.E., Redwine E.A., Freiha F.S., et al. Zonal distribution of prostatic adenocarcinoma: Correlation with histologic pattern pattern and direction of spread. Am J Surg Pathol 1988, 12(12):897-906.
7. Roehrborn C.G., Boyle P., Gould A.L., et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999, 53(3):581-589.
8. Kobayashi S., Tang R., Shapiro E., et al. Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section. J Urol 1993, 150:2002.
9. Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003, 61:2-7.
10. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387-2398.